---
title: "Xenon (XENE) Receives a Buy from RBC Capital"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295225400.md"
description: "RBC Capital analyst Brian Abrahams reiterated a Buy rating on Xenon Pharmaceuticals (XENE) with an $81.00 price target, following the stock's close at $64.55. The company holds a Strong Buy consensus with an average price target of $75.11, implying 16.36% upside. Additionally, TD Cowen maintained a Buy rating on XENE."
datetime: "2026-08-07T11:10:24.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295225400.md)
  - [en](https://longbridge.com/en/news/295225400.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295225400.md)
generator: "portal-rs"
---

# Xenon (XENE) Receives a Buy from RBC Capital

In a report released yesterday, Brian Abrahams from RBC Capital reiterated a Buy rating on Xenon, with a price target of $81.00. The company’s shares closed yesterday at $64.55.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Abrahams covers the Healthcare sector, focusing on stocks such as Gilead Sciences, Biogen, and Neurocrine. According to TipRanks, Abrahams has an average return of 14.3% and a 56.11% success rate on recommended stocks. 

Xenon has an analyst consensus of Strong Buy, with a price target consensus of $75.11, which is a 16.36% upside from current levels. In a report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $0.00 price target.

### Related Stocks

- [XENE.US](https://longbridge.com/en/quote/XENE.US.md)
- [RY.US](https://longbridge.com/en/quote/RY.US.md)
- [GILD.US](https://longbridge.com/en/quote/GILD.US.md)
- [BIIB.US](https://longbridge.com/en/quote/BIIB.US.md)
- [NBIX.US](https://longbridge.com/en/quote/NBIX.US.md)
- [TD.US](https://longbridge.com/en/quote/TD.US.md)

## Related News & Research

- [Xenon Therapeutics: Buy Rating Reiterated as AZK Progress and Strong Cash Position Support Compelling Risk-Reward; Price Target Maintained at $78](https://longbridge.com/en/news/295283436.md)
- [A Look At Xenon Pharmaceuticals (XENE) Valuation After Recent Share Price Drift Without Clear Catalyst](https://longbridge.com/en/news/278435744.md)
- [Mayfair Gold Earns Buy Rating as Fenn-Gib Development, Robust Economics Support Attractive Risk-Reward](https://longbridge.com/en/news/296821058.md)
- [CIBC Keeps Their Buy Rating on Omai Gold Mines (OMG)](https://longbridge.com/en/news/296814288.md)
- [Texas Regulator Approval of Quadvest Deal Drives Ross Fowler’s Buy Rating on H2O America, Highlighting Long-Term EPS and Valuation Upside](https://longbridge.com/en/news/296819444.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**